Viking Therapeutics, Inc. (VKTX)
Viking Therapeutics, Inc. (VKTX) from its SEC filings: 2025 revenue $0, free cash flow -$278.7 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Revenue (2025) | $0 |
| Net income | -$359.6 million |
| Free cash flow | -$278.7 million |
| Diluted EPS | $-3.19 |
| Cash | $125.8 million |
| Share count, 1 year | +4% |
| Fundamentals check | Mixed fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-24. Education only, not financial advice.